Alimera Sciences Inc. (ALIM) Sees Significant Decline in Short Interest
Alimera Sciences Inc. (NASDAQ:ALIM) was the target of a significant decline in short interest during the month of October. As of October 31st, there was short interest totalling 763,743 shares, a decline of 23.5% from the October 14th total of 998,120 shares. Approximately 1.7% of the company’s stock are short sold. Based on an average daily volume of 194,930 shares, the days-to-cover ratio is currently 3.9 days.
ALIM has been the subject of several research reports. Cowen and Company reiterated a “market perform” rating and set a $2.00 price objective on shares of Alimera Sciences in a research note on Friday, August 5th. Zacks Investment Research downgraded shares of Alimera Sciences from a “buy” rating to a “hold” rating in a research note on Wednesday, October 19th.
Alimera Sciences (NASDAQ:ALIM) opened at 1.21 on Monday. The company’s 50-day moving average is $1.37 and its 200-day moving average is $1.54. The firm’s market capitalization is $55.37 million. Alimera Sciences has a 52-week low of $1.01 and a 52-week high of $5.15.
Alimera Sciences (NASDAQ:ALIM) last released its earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($0.16) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by $0.05. The business had revenue of $8.30 million for the quarter, compared to the consensus estimate of $10.53 million. The firm’s quarterly revenue was up 20.3% compared to the same quarter last year. During the same quarter in the previous year, the business posted ($0.21) EPS. On average, analysts predict that Alimera Sciences will post ($0.54) EPS for the current year.
In other Alimera Sciences news, insider Richard S. Eiswirth, Jr. sold 51,471 shares of Alimera Sciences stock in a transaction on Thursday, September 15th. The shares were sold at an average price of $1.51, for a total value of $77,721.21. Following the transaction, the insider now directly owns 86,445 shares of the company’s stock, valued at $130,531.95. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 14.00% of the stock is currently owned by company insiders.
A number of large investors have recently added to or reduced their stakes in the company. Paloma Partners Management Co purchased a new stake in shares of Alimera Sciences during the second quarter worth approximately $140,000. PNC Financial Services Group Inc. increased its stake in shares of Alimera Sciences by 107.3% in the third quarter. PNC Financial Services Group Inc. now owns 95,100 shares of the biopharmaceutical company’s stock worth $142,000 after buying an additional 49,215 shares in the last quarter. Northern Trust Corp increased its stake in shares of Alimera Sciences by 108.9% in the third quarter. Northern Trust Corp now owns 105,320 shares of the biopharmaceutical company’s stock worth $157,000 after buying an additional 54,906 shares in the last quarter. Spark Investment Management LLC purchased a new stake in shares of Alimera Sciences during the third quarter worth approximately $262,000. Finally, Vanguard Group Inc. increased its stake in shares of Alimera Sciences by 2.3% in the second quarter. Vanguard Group Inc. now owns 1,156,193 shares of the biopharmaceutical company’s stock worth $1,422,000 after buying an additional 25,804 shares in the last quarter. Institutional investors own 31.46% of the company’s stock.
Alimera Sciences Company Profile
Alimera Sciences, Inc (Alimera) is a pharmaceutical company. The Company is engaged in the research, development and commercialization of prescription ophthalmic pharmaceuticals. The Company operates through two segments: U.S. and International. The Company focuses on diseases affecting the back of the eye or retina.
Receive News & Stock Ratings for Alimera Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alimera Sciences Inc. and related stocks with our FREE daily email newsletter.